S Grau1, S Luque2, N Campillo3, E Samsó4, U Rodríguez4, C A García-Bernedo4, E Salas3, R Sharma5, W W Hope6, J A Roberts7. 1. Pharmacy Department, Hospital del Mar, Barcelona, Spain Universitat Autónoma de Barcelona, Barcelona, Spain Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain sgrau@parcsalutmar.cat. 2. Pharmacy Department, Hospital del Mar, Barcelona, Spain Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. 3. Pharmacy Department, Hospital del Mar, Barcelona, Spain. 4. Anaesthesiology Department, Hospital del Mar, Barcelona, Spain. 5. Liverpool School of Tropical Medicine, Liverpool, UK. 6. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. 7. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Abstract
OBJECTIVES: Limited information about the pharmacokinetics of micafungin in the peritoneal cavity is available. The aim of this study was to explore the pharmacokinetics/pharmacodynamics of micafungin in plasma and peritoneal fluid in post-surgical critically ill patients with proven or suspected intra-abdominal fungal infection. METHODS: Patients were administered 100 mg/day micafungin. Serial blood and peritoneal fluid samples were collected on day 1 and day 3 (steady-state) of treatment. Concentrations were determined by validated chromatography and were subject to a population pharmacokinetic analysis with Pmetrics(®). Monte Carlo simulations were performed for AUC0-24/MIC ratios in plasma. The PTA was calculated using AUC0-24/MIC cut-offs: 285 for Candida parapsilosis and 3000 for non-parapsilosis Candida spp. RESULTS: Ten patients were included; six were male. The median (range) age, APACHE II score and Mannheim peritonitis index were 72 (43-85) years, 15 (11-36) and 26 (8-37), respectively. On day 1, median (SD) penetration of micafungin into the peritoneal cavity was 30% (30%-40%). A three-compartment model adequately described the data. The mean (SD) estimates for clearance and volume of distribution of the central compartment were 1.27 (0.75) L/h and 9.26 (1.11) L, respectively. In most patients, the PTA in plasma was ≥ 90% for MICs of 0.008-0.016 mg/L for Candida spp. and 0.125-0.25 mg/L for C. parapsilosis. CONCLUSIONS: After the first dose, micafungin at 100 mg/day achieves pharmacokinetic/pharmacodynamic targets in plasma for Candida spp. and C. parapsilosis MICs of 0.008-0.016 and 0.125-0.25 mg/L, respectively.
OBJECTIVES: Limited information about the pharmacokinetics of micafungin in the peritoneal cavity is available. The aim of this study was to explore the pharmacokinetics/pharmacodynamics of micafungin in plasma and peritoneal fluid in post-surgical critically ill patients with proven or suspected intra-abdominal fungal infection. METHODS:Patients were administered 100 mg/day micafungin. Serial blood and peritoneal fluid samples were collected on day 1 and day 3 (steady-state) of treatment. Concentrations were determined by validated chromatography and were subject to a population pharmacokinetic analysis with Pmetrics(®). Monte Carlo simulations were performed for AUC0-24/MIC ratios in plasma. The PTA was calculated using AUC0-24/MIC cut-offs: 285 for Candida parapsilosis and 3000 for non-parapsilosis Candida spp. RESULTS: Ten patients were included; six were male. The median (range) age, APACHE II score and Mannheim peritonitis index were 72 (43-85) years, 15 (11-36) and 26 (8-37), respectively. On day 1, median (SD) penetration of micafungin into the peritoneal cavity was 30% (30%-40%). A three-compartment model adequately described the data. The mean (SD) estimates for clearance and volume of distribution of the central compartment were 1.27 (0.75) L/h and 9.26 (1.11) L, respectively. In most patients, the PTA in plasma was ≥ 90% for MICs of 0.008-0.016 mg/L for Candida spp. and 0.125-0.25 mg/L for C. parapsilosis. CONCLUSIONS: After the first dose, micafungin at 100 mg/day achieves pharmacokinetic/pharmacodynamic targets in plasma for Candida spp. and C. parapsilosis MICs of 0.008-0.016 and 0.125-0.25 mg/L, respectively.
Authors: Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: María Ángeles Bordallo-Cardona; Pilar Escribano; Elia Gómez G de la Pedrosa; Laura Judith Marcos-Zambrano; Rafael Cantón; Emilio Bouza; Jesús Guinea Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Renátó Kovács; Qasem Saleh; Aliz Bozó; Zoltán Tóth; Rudolf Gesztelyi; Tamás Kardos; Gábor Kardos; István Takacs; László Majoros Journal: Mycopathologia Date: 2017-07-11 Impact factor: 2.574
Authors: Ignacio Martin-Loeches; Massimo Antonelli; Manuel Cuenca-Estrella; George Dimopoulos; Sharon Einav; Jan J De Waele; Jose Garnacho-Montero; Souha S Kanj; Flavia R Machado; Philippe Montravers; Yasser Sakr; Maurizio Sanguinetti; Jean-Francois Timsit; Matteo Bassetti Journal: Intensive Care Med Date: 2019-03-25 Impact factor: 17.440
Authors: A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: J M Boonstra; K C van der Elst; A Veringa; E M Jongedijk; R J Brüggemann; R A Koster; G A Kampinga; J G Kosterink; T S van der Werf; J G Zijlstra; D J Touw; J W C Alffenaar Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191